Annual report
4587.TEDINET S100RF5D
Period2022-01-01 → 2022-12-31
Filed2023-07-18
StandardIFRS
ConsolidatedYes
Data checks20 of 24 passed
Amends S100QIHD. Amended by S100RF5K (2023-07-18).
Key figures · 153
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥26.9bn | 2022-01-01 → 2022-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥9.4bn | 2021-01-01 → 2021-12-31 | Cons. | Revenue IFRS |
| Operating income | ¥9.0bn | 2022-01-01 → 2022-12-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥4.1bn | 2021-01-01 → 2021-12-31 | Cons. | Operating profit loss IFRS |
| Ordinary income | ¥8.1bn | 2022-01-01 → 2022-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥6.7bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥3.8bn | 2021-01-01 → 2021-12-31 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥7.6bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥6.6bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.6bn | 2021-01-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥7.6bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss IFRS |
| Net income | ¥2.6bn | 2021-01-01 → 2021-12-31 | Cons. | Profit loss IFRS |
| Total assets | ¥63.9bn | at 2022-12-31 | Cons. | Assets IFRS |
| Total assets | ¥60.1bn | at 2022-12-31 | Cons. | Total assets (5-year summary) |
| Total assets | ¥27.0bn | at 2021-12-31 | Cons. | Assets IFRS |
| Total assets | ¥26.1bn | at 2020-12-31d | Cons. | Assets IFRS |
| Total liabilities | ¥31.8bn | at 2022-12-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥1.7bn | at 2021-12-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥4.9bn | at 2020-12-31d | Cons. | Liabilities IFRS |
| Net assets / equity | ¥32.0bn | at 2022-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥30.5bn | at 2022-12-31 | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥25.4bn | at 2021-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥21.3bn | at 2020-12-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥32.0bn | at 2022-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥25.4bn | at 2021-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥21.3bn | at 2020-12-31d | Cons. | Equity attributable to owners of parent IFRS |
| Cash & equivalents | ¥5.2bn | at 2022-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥11.7bn | at 2021-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥7.1bn | at 2020-12-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | −¥83m | 2022-01-01 → 2022-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | −¥350m | 2022-01-01 → 2022-12-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥6.7bn | 2021-01-01 → 2021-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥27.4bn | 2022-01-01 → 2022-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥27.3bn | 2022-01-01 → 2022-12-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥2.3bn | 2021-01-01 → 2021-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | ¥20.8bn | 2022-01-01 → 2022-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥21.0bn | 2022-01-01 → 2022-12-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥66m | 2021-01-01 → 2021-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥58.19 | 2022-01-01 → 2022-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥51.13 | 2022-01-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥19.96 | 2021-01-01 → 2021-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥58.14 | 2022-01-01 → 2022-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥19.81 | 2021-01-01 → 2021-12-31 | Cons. | Diluted earnings loss per share IFRS |
| Net assets per share | ¥234.8 | at 2022-12-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥246.63 | at 2022-12-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥195.1 | at 2021-12-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥168.1 | at 2020-12-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 50.5% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.2% | at 2022-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 93.8% | at 2021-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 81.4% | at 2020-12-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 24.4% | 2022-01-01 → 2022-12-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 26.3% | 2022-01-01 → 2022-12-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 11.0% | 2021-01-01 → 2021-12-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 569 | at 2022-12-31 | Cons. | Number of employees |
| Employees | 141 | at 2021-12-31 | Cons. | Number of employees |
| Employees | 128 | at 2020-12-31d | Cons. | Number of employees |
| Revenue | ¥15.4bn | 2022-01-01 → 2022-12-31 | Standalone | Net sales |
| Revenue | ¥9.4bn | 2021-01-01 → 2021-12-31 | Standalone | Net sales |
| Revenue | ¥11.7bn | 2020-01-01 → 2020-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥1.0bn | 2019-01-01 → 2019-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥7.2bn | 2018-01-01 → 2018-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥6.4bn | 2017-01-01 → 2017-12-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥9.1bn | 2022-01-01 → 2022-12-31 | Standalone | Operating income |
| Operating income | ¥4.4bn | 2021-01-01 → 2021-12-31 | Standalone | Operating income |
| Ordinary income | ¥8.8bn | 2022-01-01 → 2022-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥4.8bn | 2021-01-01 → 2021-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥7.0bn | 2020-01-01 → 2020-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥707m | 2019-01-01 → 2019-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.8bn | 2018-01-01 → 2018-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.2bn | 2017-01-01 → 2017-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥6.9bn | 2022-01-01 → 2022-12-31 | Standalone | Income before income taxes |
| Profit before tax | ¥4.8bn | 2021-01-01 → 2021-12-31 | Standalone | Income before income taxes |
| Net income | ¥4.3bn | 2022-01-01 → 2022-12-31 | Standalone | Profit loss |
| Net income | ¥3.6bn | 2021-01-01 → 2021-12-31 | Standalone | Profit loss |
| Net income | ¥4.4bn | 2020-01-01 → 2020-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥488m | 2019-01-01 → 2019-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥2.8bn | 2018-01-01 → 2018-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥2.3bn | 2017-01-01 → 2017-12-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥55.2bn | at 2022-12-31 | Standalone | Assets |
| Total assets | ¥26.6bn | at 2021-12-31 | Standalone | Assets |
| Total assets | ¥26.3bn | at 2020-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥17.8bn | at 2019-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥20.0bn | at 2018-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥16.5bn | at 2017-12-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥25.8bn | at 2022-12-31 | Standalone | Liabilities |
| Total liabilities | ¥1.6bn | at 2021-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥29.4bn | at 2022-12-31 | Standalone | Net assets |
| Net assets / equity | ¥25.0bn | at 2021-12-31 | Standalone | Net assets |
| Net assets / equity | ¥21.2bn | at 2020-12-31d | Standalone | Net assets |
| Net assets / equity | ¥17.0bn | at 2019-12-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥17.4bn | at 2018-12-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥14.7bn | at 2017-12-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥847m | at 2022-12-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥11.7bn | at 2021-12-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥11.7bn | at 2021-12-31 | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥7.1bn | at 2020-12-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥7.0bn | at 2019-12-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥6.9bn | at 2018-12-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥3.5bn | at 2017-12-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥6.7bn | 2021-01-01 → 2021-12-31 | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.7bn | 2020-01-01 → 2020-12-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥242m | 2019-01-01 → 2019-12-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥4.5bn | 2018-01-01 → 2018-12-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.0bn | 2017-01-01 → 2017-12-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥2.3bn | 2021-01-01 → 2021-12-31 | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.2bn | 2020-01-01 → 2020-12-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥138m | 2019-01-01 → 2019-12-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.3bn | 2018-01-01 → 2018-12-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥4.2bn | 2017-01-01 → 2017-12-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥66m | 2021-01-01 → 2021-12-31 | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥237m | 2020-01-01 → 2020-12-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥29m | 2018-01-01 → 2018-12-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥170m | 2017-01-01 → 2017-12-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥33.11 | 2022-01-01 → 2022-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥27.98 | 2021-01-01 → 2021-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥35.4 | 2020-01-01 → 2020-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-3.9 | 2019-01-01 → 2019-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥22.42 | 2018-01-01 → 2018-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥19.35 | 2017-01-01 → 2017-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥27.78 | 2021-01-01 → 2021-12-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥34.26 | 2020-01-01 → 2020-12-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥21.33 | 2018-01-01 → 2018-12-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥17.79 | 2017-01-01 → 2017-12-31d | Standalone | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥226.48 | at 2022-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥192.39 | at 2021-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥168.1 | at 2020-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥134.97 | at 2019-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥138.73 | at 2018-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥119.31 | at 2017-12-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 53.2% | at 2022-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 93.8% | at 2021-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 80.5% | at 2020-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 94.8% | at 2019-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 86.6% | at 2018-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 88.6% | at 2017-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 15.8% | 2022-01-01 → 2022-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 15.6% | 2021-01-01 → 2021-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 23.4% | 2020-01-01 → 2020-12-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 17.3% | 2018-01-01 → 2018-12-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 17.4% | 2017-01-01 → 2017-12-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 130,010,400 | at 2022-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 130,010,400 | at 2021-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 125,910,400 | at 2020-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 125,310,400 | at 2019-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 125,310,400 | at 2018-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 122,714,400 | at 2017-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 155 | at 2022-12-31 | Standalone | Number of employees |
| Employees | 141 | at 2021-12-31 | Standalone | Number of employees |
| Employees | 128 | at 2020-12-31d | Standalone | Number of employees |
| Employees | 107 | at 2019-12-31d | Standalone | Number of employees |
| Employees | 104 | at 2018-12-31d | Standalone | Number of employees |
| Employees | 83 | at 2017-12-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 15
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-01-01 → 2022-12-31 | −¥27m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-01-01 → 2022-12-31 | −¥27m |
| Drug Discovery And Development Businessreportable segment | employees | at 2022-12-31 | 155 pure |
| Drug Discovery And Development Businessreportable segment | revenue | 2022-01-01 → 2022-12-31 | ¥15.4bn |
| Drug Discovery And Development Businessreportable segment | revenue external | 2022-01-01 → 2022-12-31 | ¥15.4bn |
| Drug Discovery And Development Businessreportable segment | segment profit | 2022-01-01 → 2022-12-31 | ¥9.2bn |
| Radiopharmaceuticals Businessreportable segment | employees | at 2022-12-31 | 414 pure |
| Radiopharmaceuticals Businessreportable segment | revenue | 2022-01-01 → 2022-12-31 | ¥11.5bn |
| Radiopharmaceuticals Businessreportable segment | revenue external | 2022-01-01 → 2022-12-31 | ¥11.4bn |
| Radiopharmaceuticals Businessreportable segment | revenue intersegment | 2022-01-01 → 2022-12-31 | ¥27m |
| Radiopharmaceuticals Businessreportable segment | segment profit | 2022-01-01 → 2022-12-31 | ¥236m |
| —segment total | revenue | 2022-01-01 → 2022-12-31 | ¥26.9bn |
| —segment total | revenue external | 2022-01-01 → 2022-12-31 | ¥26.9bn |
| —segment total | revenue intersegment | 2022-01-01 → 2022-12-31 | ¥27m |
| —segment total | segment profit | 2022-01-01 → 2022-12-31 | ¥9.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,501
| Item | Context | Value | Unit |
|---|---|---|---|
| Other income IFRS | Prior1YearDuration | 46624000 | JPY |
| Other income IFRS | CurrentYearDuration | 13517000 | JPY |
| Other expenses IFRS | Prior1YearDuration | 191000 | JPY |
| Other expenses IFRS | CurrentYearDuration | 11073000 | JPY |
| Operating profit loss IFRS | Prior1YearDuration | 4066246000 | JPY |
| Operating profit loss IFRS | CurrentYearDuration | 8980196000 | JPY |
| Finance income IFRS | Prior1YearDuration | 309901000 | JPY |
| Finance income IFRS | CurrentYearDuration | 189047000 | JPY |
| Finance costs IFRS | Prior1YearDuration | - | JPY |
| Finance costs IFRS | CurrentYearDuration | 2312643000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YearDuration | -572383000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | CurrentYearDuration | -203275000 | JPY |
| Profit loss before tax IFRS | Prior1YearDuration | 3803764000 | JPY |
| Profit loss before tax IFRS | CurrentYearDuration | 6653325000 | JPY |
| Income tax expense IFRS | Prior1YearDuration | 1230532000 | JPY |
| Income tax expense IFRS | CurrentYearDuration | -901033000 | JPY |
| Profit loss IFRS | Prior1YearDuration | 2573232000 | JPY |
| Profit loss IFRS | CurrentYearDuration | 7554358000 | JPY |
| Profit loss attributable to owners of parent IFRS | Prior1YearDuration | 2573232000 | JPY |
| Profit loss attributable to owners of parent IFRS | CurrentYearDuration | 7554358000 | JPY |
| Profit loss IFRS | Prior1YearDuration | 2573232000 | JPY |
| Profit loss IFRS | CurrentYearDuration | 7554358000 | JPY |
| Basic earnings loss per share IFRS | Prior1YearDuration | 19.96 | |
| Basic earnings loss per share IFRS | CurrentYearDuration | 58.19 | |
| Diluted earnings loss per share IFRS | Prior1YearDuration | 19.81 | |
| Diluted earnings loss per share IFRS | CurrentYearDuration | 58.14 | |
| Profit loss IFRS | Prior1YearDuration | 2573232000 | JPY |
| Profit loss IFRS | CurrentYearDuration | 7554358000 | JPY |
| Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRS | Prior1YearDuration | 972945000 | JPY |
| Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRS | CurrentYearDuration | -869301000 | JPY |
| Remeasurements of defined benefit plans net of tax items that will not be reclassified to profit or loss oci IFRS | Prior1YearDuration | - | JPY |
| Remeasurements of defined benefit plans net of tax items that will not be reclassified to profit or loss oci IFRS | CurrentYearDuration | -78707000 | JPY |
| Total of items that will not be reclassified to profit or loss oci IFRS | Prior1YearDuration | 972945000 | JPY |
| Total of items that will not be reclassified to profit or loss oci IFRS | CurrentYearDuration | -948009000 | JPY |
| Other comprehensive income IFRS | Prior1YearDuration | 972945000 | JPY |
| Other comprehensive income IFRS | CurrentYearDuration | -948009000 | JPY |
| Comprehensive income IFRS | Prior1YearDuration | 3546177000 | JPY |
| Comprehensive income IFRS | CurrentYearDuration | 6606348000 | JPY |
| Comprehensive income attributable to owners of parent IFRS | Prior1YearDuration | 3546177000 | JPY |
| Comprehensive income attributable to owners of parent IFRS | CurrentYearDuration | 6606348000 | JPY |
| Comprehensive income IFRS | Prior1YearDuration | 3546177000 | JPY |
| Comprehensive income IFRS | CurrentYearDuration | 6606348000 | JPY |
| Equity IFRS | Prior2YearInstant_ShareCapitalIFRSMember | 3933885000 | JPY |
| Equity IFRS | Prior2YearInstant_CapitalSurplusIFRSMember | 10305306000 | JPY |
| Equity IFRS | Prior2YearInstant_TreasurySharesIFRSMember | -655383000 | JPY |
| Equity IFRS | Prior2YearInstant_RetainedEarningsIFRSMember | 7503531000 | JPY |
| Equity IFRS | Prior2YearInstant_OtherComponentsOfEquityIFRSMember | 191468000 | JPY |
| Equity IFRS | Prior2YearInstant_EquityAttributableToOwnersOfParentIFRSMember | 21278808000 | JPY |
| Equity IFRS | Prior2YearInstant | 21278808000 | JPY |
| Profit loss IFRS | Prior1YearDuration_ShareCapitalIFRSMember | - | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 20 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | mismatch |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | mismatch |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | mismatch |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | mismatch |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |